bladder cancer

October 2013 New Urology Products & ServicesThe latest products and services from Cook Medical, American Medical Systems, Dialog Medical, Astellas Pharma U.S., Giffen Solutions, the Société Internationale d’Urologie, Merck Consumer Care, and the Bladder Cancer Advocacy Network.
Urology Product PreviewDrugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.
‘Scent device’ may help detect bladder cancerBritish researchers have developed a device that they say is able to read odors in urine to help diagnose patients with early signs of bladder cancer.
Best of AUA 2013: Outcomes AnalysisDanil V. Makarov, MD, MHS, presents the take home messages on outcomes analysis.
Best of AUA 2013: Bladder CancerEdmund Chiong, MD, presents the take home messages on bladder cancer from the AUA annual meeting in San Diego.
Closer surveillance, treatment needed in bladder CaMore intense surveillance and treatment in the first 2 years after a bladder cancer diagnosis could reduce the number of patients whose cancer recurs and lower the death rate from this disease, according to researchers from UCLA’s Jonsson Comprehensive Cancer Center.
MicroRNAs may predict urothelial cancer progressionMicroRNA expression appears to serve as a biomarker for predicting the progression of bladder urothelial carcinoma, the authors of a study from Israel reported.
Bladder Ca: New findings on its course, metastasisTwo recent studies appear to shed light on the effect of smoking on bladder cancer outcomes and the role a certain protein plays in metastatic disease.
Bladder cancer remission improved by adding electromotive mitomycin to BCGIn patients with stage pT1 urothelial bladder cancer, intravesical bacillus Calmette-Guérin (TheraCys, TICE BCG) combined with electromotive mitomycin-C produces higher remission rates and longer remission times than BCG alone, Italian researchers reported.
Post-cystectomy survival predicted by hospital volumeHospital volume is a key predictor of survival for patients with urothelial bladder cancer undergoing radical cystectomy and has a greater impact than surgeon volume, findings from a retrospective analysis suggest.